They also discovered that the SMO inhibitor (LDE225) curtailed the expression of matrix metalloproteinases (MMPs) and GLI-1/2, consequently reducing the invasiveness and metastatic propensity of hepatocellular carcinoma (HCC) cells [43]. Here, GLI1 is linked to hepatocellular carcinoma.